Cargando…

The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article

Non-muscle invasive bladder cancer (NMIBC) is a common urological malignancy, and bacillus Calmette-Guérin (BCG) therapy is the gold standard treatment in intermediate and high-risk groups. However, BCG failure occurs in a significant proportion of patients, emphasizing the need for effective altern...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kodera, Ahmed, Mohammed, Mahmoud, Lim, Paul, Abdalla, Omer, Elhadi, Mohammed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Urology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369196/ https://www.ncbi.nlm.nih.gov/pubmed/37503461 http://dx.doi.org/10.7759/cureus.40962

Ejemplares similares

Systemic Bacillus Calmette-Guérin (BCG) Infection With Renal Involvement: A Rare Complication of BCG Immunotherapy
por: Afonso, Raquel, et al.
Publicado: (2022)

Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer
por: Jamil, Marcus L, et al.
Publicado: (2019)

Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022)

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)

Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Publicado: (2021)

Vertebral Osteomyelitis Secondary to Bacillus Calmette-Guérin Instillation Therapy for Transitional Cell Carcinoma In Situ
por: Jaber, Tariq M, et al.
Publicado: (2021)

Lumbosacral Vertebral Osteomyelitis With Iliopsoas and Epidural Abscess Following Intravesical Bacillus Calmette-Guérin Therapy
por: Abbas, Anas M, et al.
Publicado: (2023)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

VARIABILITY OF BCG STRAINS (BACILLUS CALMETTE-GUÉRIN)
por: Suter, W. Emanuel, et al.
Publicado: (1951)

Bacillus Calmette-Guerin (BCG) vaccine in Iran
por: Fallah, Fatemeh, et al.
Publicado: (2018)

Bacillus Calmette-Guerin (BCG): the adroit vaccine
por: Adesanya, Oluwafolajimi A., et al.
Publicado: (2021)

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2016)

Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Treatment of non-muscle invasive bladder cancer with Bacillus Calmette–Guerin (BCG): Biological markers and simulation studies
por: Kiselyov, Alex, et al.
Publicado: (2015)

Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Li, Roger, et al.
Publicado: (2017)

Septic Shock After Intravesical Therapy With Bacillus Calmette-Guerin: A Case Report of a Rare Life-Threatening Complication
por: Fernandes, Pedro Francisco, et al.
Publicado: (2023)

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international individual patient data survey (IPDS)
por: Witjes, J Alfred, et al.
Publicado: (2013)

Disseminated Bacillus Calmette-Guérin (BCG) infections in infants with immunodeficiency
por: Al-Hammadi, Suleiman, et al.
Publicado: (2017)

Tuberculous epididymo-orchitis secondary to Bacillus Calmette-Guérin (BCG) in non-muscular invasive bladder cancer
por: Lara Moscoloni, Luis Felipe, et al.
Publicado: (2021)

Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing.
por: Pryor, K., et al.
Publicado: (1995)

Renal Tuberculosis Following Intravesical Bacillus Calmette–Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer
por: Bajramovic, Senad, et al.
Publicado: (2020)

Bacillus Calmette-Guérin (BCG) therapy lowers the incidence of Alzheimer’s disease in bladder cancer patients
por: Gofrit, Ofer N., et al.
Publicado: (2019)

Immunotherapy With Bacillus Calmette-Guerin (BCG) in a 16-Year-Old With Urothelial Bladder Carcinoma
por: Martinez-Thomas, Jose M, et al.
Publicado: (2022)

Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation: A case report
por: Moussa, M., et al.
Publicado: (2018)

Goldilocks and the BCG: Bacillus Calmette-Guérin Dose Reduction in the Age of Shortage
por: Nikas, Christine V., et al.
Publicado: (2020)

Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer
por: Deng, Tuo, et al.
Publicado: (2017)

Instillation Strategies for Non-Muscle-Invasive Bladder Cancer in the Bacillus Calmette-Guerin Shortage Era: A Simple Solution for BCG Discontinuation
por: Lin, Po-Ting, et al.
Publicado: (2022)

Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer
por: Suh, Jungyo, et al.
Publicado: (2020)

Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
por: Kim, Hyung Suk, et al.
Publicado: (2021)

Treatment strategies for the Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2023)

Bacillus Calmette-Guérin in the management of superficial bladder cancer
por: Kapoor, Rakesh, et al.
Publicado: (2008)

Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure
por: Shantharam, Govind, et al.
Publicado: (2021)

Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
por: Cooper, Owen Alan Edwards, et al.
Publicado: (2023)

Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
por: Ali-El-Dein, Bedeir, et al.
Publicado: (2013)

Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-α
por: Saban, Marcia R, et al.
Publicado: (2008)

Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)
por: Thyavihally, Yuvaraja B., et al.
Publicado: (2022)

Guillain Barré syndrome associated with bladder instillation of Bacille Calmette Guérin (BCG)
por: Webb, Karmel, et al.
Publicado: (2018)

The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette–Guérin versus BCG alone in non-muscle-invasive bladder cancer: A randomized controlled trial
por: El Azab, Abdalla, et al.
Publicado: (2023)

Bacillus Calmette–Guérin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer
por: Su, Fei, et al.
Publicado: (2022)

Replacement Instead of Discontinuation of Bacillus Calmette-Guérin Instillation in Non-Muscle-Invasive Bladder Cancer
por: Lin, Po-Ting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6hmpm06dto7bdihu2elmi4shh6